Introduction: Over the past decades, allogeneic stem cell transplantation (allo-SCT) has been performed with increasing success in children with particularly unfavorable acute leukemias. The success of this treatment modality is mainly affected by recurrence of the underlying disease. Although the benefits of immunotherapy for CML patients as treatment for relapse is well documented1,2 there are fewer reports of successful response in patients with acute leukemias3,4. Moreover, clinical response has mostly been associated with measurable graft-versus-host disease (GVHD), possibly due to high cell doses given in the situation of frank hematological relapse. However, there is evidence that low dose of donor Tcells may also induce efficient immunoresponse in patients with small leukemia burden to re-achieve long term remission5. We have recently shown in a study of 55 patients with acute leukemias that patients who demonstrate increasing amounts of autologous marrow repopulation (increasing mixed chimerism; in-MC) have a significantly enhanced risk of relapse (p<0.0001)6. Therefore we investigated whether frank hematological relapse could be prevented by withdrawal of CSA and/or by administration of low dose DLI (dosage: 10-4 to 10-6) on the basis of in-MC in a large prospective multi-center study. Patients: Between January 1996 and December 2001 191 allo-SCT have been performed in children with ALL in 13 pediatric transplant centers in Germany. Informed consent of patients and parents were appropriate was obtained according to institutional guidelines. All data were analyzed up to May 2002. Methods: Determination of individual hematopoietic chimerism in short time intervals (weekly during the first 100 days thereafter once a month) was performed by a semiquantitative PCR approach based on amplification of STR markers as described previously. Additional immunotherapy was offered to patients who developed in-MC posttransplant as described in detail elsewhere.7-8
Results: 18 patients were excluded either due to lack of informative markers (n=2) or because no regular posttransplant samples were sent to the laboratory. This left 173 patients open to be studied. During follow-up 110 patients showed complete chimerism (CC; n=64) or low level MC (LL-MC with a maximum of 1% autologous cells; n=46), 47 patients developed in-MC and 16 children showed decreasing MC (de-MC). Of the 47 patients with in-MC additional immunotherapy was offered to 32 patients whereas 15 patients with in-MC received no additional treatment. In the group of patients showing CC/LL-MC (n=110) during follow-up only 9 patients relapsed, whereas 27/47 patients with in-MC developed relapse (P<0.0001). Further analysis of the latter group of patients with in-MC showed, that 16/32 patients with additional immunotherapy responded to treatment, 13/16 remained in CCR, 3 patients died due to infections. In the group of patients with in-MC who received no additional treatment 11/15 relapsed, 3/15 rejected their graft and one patient died to TRM reasons. Only one patient survived after having rejected the graft. However, this patient received a second transplant. Altogether 16/32 patients with in-MC and additional treatment relapsed, whereas in the group of 15 patients with in-MC who did not receive prophylactic treatment 11/15 patients died due to relapse (P<0.0001). The event free survival (EFS) in the group of patients with in-MC and immunotherapy is 0.37 (n=32; SE: 0.09) vs. 0.0 in the group of patients without additional therapy (n=15; SE: 0.0) (P=0.0003). Severe GVHD was not seen in any patients who received immunotherapy. In addition, non of the 16 patients with de-MC relapsed posttransplant. Discussion: Serial and quantitative analysis of hematopoietic chimerism identifies those patients with the highest risk of relapse and graft rejection. It provides a reliable algorithm which justifies additional treatment to individual patients to prevent relapse or graft rejection. Initiation of prophylactic immunotherapy on the basis of in-MC offers the possibility to prevent frank hematological relapse in a great cohort of children with ALL. Most notable, no single patient who developed in-MC survived without additional treatment. The cohort of patients with in-MC clearly benefit from immunotherapy. As no patient developed fatal GVHD after additional therapy was offered escalating doses of DLI' s might be feasible to further improve outcome. However, it will be the aim of future studies to optimize treatment strategies and reveal the optimal dose of lymphocyte infusions according to the individual donor/recipient constellation. Investigation of donor-and recipient-derived hemopoiesis (chimerism) by molecular techniques has become a routine diagnostic approach to the surveillance of patients after allogeneic stem cell transplantation. The analysis of chimerism during the immediate post-transplant period permits early assessment of successful engraftment or graft failure1. Moreover, the monitoring of residual recipient cells in peripheral blood (PB) can provide timely indication of impending allograft rejection and, in patients with leukemia, impending disease recurrence by revealing an increasing proportion of recipient-derived cells1,2. PCR-based chimerism assays analyzing highly polymorphic microsatellite markers permit the detection of residual autologous cells at a sensitivity of about 1-5%. When investigating chimerism in total leukocyte preparations from PB, this level of sensitivity may not be sufficient to allow early assessment of impending complications1,3. It is possible to overcome this problem by investigating chimerism in specific leukocyte subsets of interest isolated by flow sorting or by immunomagnetic bead separation. Since residual recipient-derived cells can be detected within the individual leukocyte fractions with similar sensitivity, it is possible to identify and monitor minor autologous populations that escape detection in total PB leukocyte samples. The overall sensitivity of chimerism assays achievable by investigating specifically enriched leukocyte subsets is in a range of 0.1-0.01%3, i.e. one to two logs higher than analysis of total leukocyte preparations. We have prospectively investigated lineage-specific chimerism within flow-sorted leukocyte subsets in a series of 100 pediatric patients between day +14 and +100 after allogeneic stem cell transplantation. Patients with SCID, patients with primary graft failure and patients who died before day +50 post-transplant were excluded from the analysis. Hence, a total of 83 transplantations in 76 patients could be evaluated. The underlying diseases included different types of leukemia (n= 48; acute, n=38; chronic, n=10), and non-malignant disorders (n=28; inborn errors, n=22; severe aplastic anemia, n=6). The conditioning regimen was myeloablative in 52 cases and non-myeloablative (reduced intensity conditioning) in 31 instances. The donors were matched siblings (MSD; n=21), parents (MMFD; n=19) or unrelated individuals (MUD; n=43). T cell depletion was performed in 43 instances, in patients receiving peripheral blood stem cell transplantation (PBSCT). The cell populations investigated included granulocytes, monocytes, NK-cells, T-cells (helper and suppressor subsets), B-cells, and stem cells. The cell populations were isolated by targeting appropriate combinations of the following surface markers: CD3+, CD4+, CD8+, CD14+, CD15+, CD34+, CD38+, CD45+, and CD56+. For the detection of residual malignant cells, specific populations were targeted according to the original immunophenotype of the leukemic clone (e.g. CD34+/CD19+ in patients with B cell precursor acute lymphoblastic leukemia whose blast cells displayed these markers at diagnosis). The cell subsets isolated by flow-sorting were subjected to PCR analysis of chimerism using a panel of highly polymorphic microsatellite (STR) markers1,4. Children transplanted from sex-mismatched donors were studied by dual color FISH.
Detection of imminent relapse by serial analysis of leukemia lineage-specific chimerism
In some patients, investigation of entire leukocyte fractions from PB revealed reappearance of autologous cells (mixed chimerism) shortly before diagnosis of relapse. In all other instances, however, analysis of chimerism within total leukocytes has not shown any changes indicative of impending relapse. Serial investigation of specific leukocyte subsets derived from PB or bone marrow (BM) revealed informative changes in most patients who have later experienced hematologic relapse. These patients revealed either persistence or reappearance of autologous allelic patterns within cell populations expected to harbor leukemic cells, if present. Occasionally, however, the only observation made before hematologic relapse was lineage-specific chimerism kinetics suggestive of graft rejection. Prediction of graft rejection by the monitoring of chimerism within lymphocyte subsets Patients who received reduced intensity conditioning revealed leukocytes of recipient genotype more frequently than patients after myeloablative conditioning (38% vs 74%). The higher incidence of mixed or recipient chimerism was attributable to myeloid cells (CD14+ and CD15+), but no differences were observed within the lymphocyte populations. By contrast, in patients who had received T cell depleted grafts, there was a strong correlation with the presence of mixed or recipient chimerism within T cells (CD3+; 91% in T cell depleted vs 20% in T cell replete grafts) and NK cells (CD56+; 39% vs 20%). Detection of mixed chimerism within lymphocyte populations was followed by late rejection in 24% of the patients. In several instances, serial analysis revealed an increasing recipientspecific allelic pattern prior to overt graft rejection. The correlation between the observation of mixed or recipient chimerism and graft rejection was higher for NK cells (CD56+) than for T helper (CD3+/CD4+) or T suppressor (CD3+/CD8+) cells (47% vs 27% vs 22%). All patients who displayed recipient chimerism in CD56+ cells between days +14 and +35 rejected the graft. By contrast, virtually all patients who experienced late graft rejection showed pure donor genotype within the CD14+ and CD15+ cells during the same period. Taken together, the depletion of T cells had greater impact on the occurrence of T cell chimerism than the conditioning modality applied. The observation of recipient chimerism within the CD56+ cell subset was highly predictive for the occurrence of late graft rejection. Relapse and rejection still are prominent causes of treatment failure. Since both are mediated by cells of autologous origin they are potentially predictable by detection of autologous DNA in alloHCT recipients. In our paper, we try to estimate weather hematopoietic chimerism monitoring is a valuable tool to detect imminent treatment failure. Materials: Chimerism was monitored in 57 children, aged from 2 mo. to 21 yrs with male to female ratio of 1.5. Diagnoses varied and included pediatric malignancies (ALL 20, AML 9, CML 8, MDS 9, NHL 2) and non-malignant disorders (BDA 2, SAA 2, SCID 2, Omenn S. 1, Osteopetrosis 1, WAS 1). Twenty three children were transplanted from HLA-identical siblings (HLA ID SIB), 18 from partially matched family donors (PMFD) and 16 from matched unrelated donors (MUD). No TBI was used in conditioning. GvHD prophylaxis varied according to donor type . Chimerism was monitored in peripheral blood MNCs (PB) collected weekly from engraftment till discharge, then during each routine medical check-up. When autologous cells were detected in PB or if patient's condition deteriorated, chimerism was also assessed in bone marrow MNCs (BM). Methods: Chimerism was monitored by semiquantitative PCR-STR method with fluorescent primers complementary to five STR loci. PCR -products were analyzed with automated DNA sequencer. Results: In 3 children after alloHCT exclusively autologous cells reemerged, 2 of them recovered with leukemic cells and one experienced autologous recovery. Twenty seven children were complete donor-type chimeras. None experienced rejection. Two out of 24 children with malignancies relapsed while being complete donor chimeras. However, one relapsed 100 day after last chimerism assessment was performed. Mixed chimerism was detected in 27 children. None of 3 children with stable chimerism experienced relapse or rejection so far. All 11 children with increasing number of detectable autologous cells relapsed (3) or rejected their grafts finally (8). Thirteen children eliminated autologous cells, either spontaneously or after immune manipulation. None of children with decreasing mixed chimerism experienced graft rejection, one relapsed in CNS while being in remission in BM. Conclusions: Mixed chimerism is common phenomenon after alloHCT with non-TBI conditioning. Increase in number of autologous cells clearly indicates imminent treatment failure. Clinical significance of stable mixed chimerism remains to be determined.
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The implication of serial hematopoetic chimerism analysis in children with severe aplastic anemia after allogenic stem cell transplantation (SCT)
W. Hoelle, H. Kreyenberg, P. Lang, J. Greil, D. Niethammer, T. Klingebiel, J. Beck, P. Bader (Tubingen, Frankfurt, Greifswald, D)
In a multicenter study 34 transplantations in 32 paediatric patients have been performed for severe aplastic anemia. The median follow up was 30 month (1 -95 month). Posttransplant engraftment has been monitored by sequential analysis of chimerism using quantitative PCR based amplification of short tandem repeat (STR) markers. Weekly analysis up to 100 days post transplant and then once a month were performed. During the course of follow up 9 patients developed mixed chimerism (MC), one patient failed to achieve sustained engraftment an 24 became complete chimeras (CC) at all subsequent analysis. Two patients with MC (2 / 9) showed decreasing amounts of autologous cells and became CC. They are in sustained complete remission. Four patients developed an increasing MC (in -MC). In two of them (2 / 4) autologous cells rapidly increased and they finally rejected their graft. A second transplantation has been performed. The patients then became CC and remain in complete remission (CR). The other two patients (2 / 4) with in -MC received additional immunomodulating therapy by repetitive transfusion of lowdose DLI (2,5 x 10*4 T -Cells / kg) when the amount of autologous cells increased over 30 %. Both patients responded to the therapy. The amount of autologous cells decreased and the patients remain disease free. Non of them developed any GvHD. Three patients expressed stable MC (3 / 9) with little variation in the amount of autologous cells. In one patient MC never exceeded over 30 %. Two expressed high levels of MC with approximately 60 % autologous cells. In one patient cyclosporin A was withdrawn without a persisting effect on the MC. All three patients remain in complete remission. Conclusion: Rapid increasing mixed chimerism is associated with graft rejection in children transplanted for SAA. Low dose DLI in children with SAA is feasible and may help to prevent graft rejection without inducing GvHD. However persisting high amounts of autologous cells are also found in disease free patients. Further information about the individual risk of graft rejection may be obtained by analysis of lineage specific chimerism.
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MRD based allocation to SCT or chemotherapy in children with intermediate-risk relapse of ALL
C. Eckert, A. von Stackelberg, K. Seeger, R. Hartmann, T. Taube, A. Guggemos, G. Henze (Berlin, D)
In several ALL-frontline-trials the value of minimal residual disease (MRD) as stratification parameter is under investigation. Since indication of allogeneic stem-cell transplantation (SCT) remains unclear for children with intermediate-risk relapse of ALL, we analysed the potency of MRD-monitoring to predict outcome in this patient group, allowing to define patients with high risk for subsequent relapse and therefore eligible for SCT and others with an acceptable prognosis after chemotherapy alone. In 87 children with intermediate-risk relapse of ALL (S2), MRD status has been monitored after the second chemotherapycourse (F2, week 5) of the ALL-REZ BFM protocol. Quantitative assessment of residual disease was performed by Real-Time PCR using T-cell receptor and immunoglobulin gene rearrangements as clone-specific targets. Two clonal markers are required, at least one of them with a sensitivity of 10-4. In patients with MRD <10-3 (n=52), the probability of event-free survival (EFS), relapse-free survival, and overall survival at 4 years and a median follow up of 1.4 years was 0.90 +/-0.06, 0.92 +/-0.05 and 0.98 +/-0.02, as compared to, 0.44 +/-0.13, 0.56 +/-0.15 and 0.30 +/-0.22 in patients with MRD +/-;10-3 (n=35) (p<0.001 each) (see figure) . A multivariate Cox Regression analysis including all relevant prognostic parameters revealed the MRD status after course F2 as the most powerful independent predictor of EFS (p=0.001, risk-ratio=10.1). The MRD-status after the 2nd induction-course in children with intermediate-risk relapse of ALL treated according to the ALL-REZ BFM protocols is suitable to distinguish patients with high risk for subsequent relapse from those with favorable prognosis after chemotherapy alone. MRD will be implemented in the new trial ALL-REZ BFM 2002 as criteria for allocation to allogeneic SCT or chemotherapy as post-remission treatmentstrategies. The benefit of this approach will be evaluated by comparison with historical controls.
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Summary and Conclusions: P. Bader, J. J M van Dongen
Preface:
Although considerable progress has been made in the field of stem cell transplantation in pediatric hemato-oncology, relapse of the underlying disease has remained a major cause of treatment failure. Successful post-relapse therapy in patients with acute leukemias and advanced myelodysplastic syndrome (MDS) who received allogeneic stem cell transplantation (allo-SCT) is mainly restricted to a second allograft with considerable treatment related mortality (TRM). Therefore great efforts have been undertaken to identify patients with highest risk for post-transplant relapse using PCR-based technologies. Two different approaches can potentially identify these high-risk patients: i) characterization of hematopoietic chimerism and ii) analysis of minimal residual disease (MRD).
Summary:
In the first contribution, PD Dr. P. Bader (Tübingen, DE) presented a large prospective multi-center trial focusing on 163 children with ALL in whom chimerism was serially assessed in whole peripheral blood at high frequency (weekly during the first 100 days, thereafter once a month). Additional immunotherapy was offered to those patients who developed increasing mixed chimerism (in-MC). The otherwise fatal outcome of this patient group could be improved to an EFS of 38%. Analysis of chimerism in leukocyte subpopulations may be of additional value, because this improves the limited sensitivity of the technique. This was demonstrated by Prof. Th. Lion (Vienna, AT), who presented a prospective trial in which chimerism was assessed within different hematopoietic lineages. Indeed a higher sensitivity was obtained and MC could be detected in all patients before relapse or graft rejection. However, an algorithm to predict which patients will definitively relapse or reject their grafts could not be found. In a smaller study Dr. D. Turkiewicz (Wroclaw, PL) could confirm the importance of serial chimerism investigations in peripheral blood. Dr. W. Hoelle (Tübingen, DE) presented a prospective trial in children transplanted for severe aplastic anemia (SAA) and could show that low dose donor-lymphocyte infusion can convert MC back to complete chimerism (CC) and thereby avoid graft rejection in patients with rapid recurrence of host derived hematopoietic cells. PCR-based detection of MRD in children with acute lymphoblastic leukemia (ALL) is technically more complex than analysis of post-transplant chimerism. At present, PCR analysis of immunoglobulin-and T-cell receptor gene rearrangements serves as the gold standard for MRD detection in patients with ALL. In his presentation, Prof. J.J.M. van Dongen (Rotterdam, NL) detailed the urgent need for standardized multi-center trials because of the complexity of PCR-based MRD techniques. He showed, that under his coordination an European Study Group on MRD detection in ALL has been founded and will provide the scientific community with reliable prospective data in the near future. Dr. C. Eckert (Berlin, DE) presented a retrospective study in which she could show, that standardized MRD detection in children with relapsed ALL can serve as a diagnostic tool for improved identification of patients that might benefit from SCT. In patients with acute myeloid leukemia (AML) and advanced MDS the determination of MRD is more difficult due to the fact that a uniform technique is not yet available. Prof. A. Biondi (Monza, IT) presented a new real-time-PCR approach for the detection of Wilms tumor gene 1 (WT-1) transcripts, which are highly expressed in virtually all patients with AML, advanced MDS, and JMML. As the WT-1 gene is also expressed in normal CD34 progenitor cells, the detection of MRD using this approach might be restricted to analysis of peripheral blood.
Conclusions:
So far the serial and quantitative analysis of hematopoietic chimerism in peripheral blood could identify patients at highest risk of relapse. Moreover chimerism studies provide a basis for additional immunotherapy to prevent relapse in malignant diseases and to prevent graft rejection in non-malignant diseases. Formally, chimerism studies can not discriminate between imminent relapse and graft rejection. However, this can be evaluated by standardized MRD techniques, which are now available for virtually all ALL patients and 30-40% of AML patients. Prospective data on the clinical impact of posttransplant MRD detection are not yet generated, but will be available in the near future. Poor prognosis of certain types of central nervous system (CNS) tumours and unacceptable long term sequelae of radiotherapy, especially in young children led to develop new treatment strategies in paediatric brain tumours. In this respect, there has been much recent interest in the use of HDC followed by autologous stem cell transplantation (ASCT). Alkylating agents appear the most appropriate class of drugs to be used in a high-dose setting, since they are among the most active drugs against CNS tumours and are characterized by a step linear-log response relationship. At Institut Gustave Roussy, Villejuif, we have mainly used a combination of Busulfan and Thiotepa. Thiotepa and its major metabolite, TEPA, reach cerebrospinal fluid (CSF) concentrations that are approximately equivalent to the plasma concentrations at the same time. They show in vitro cytocidal activity with a steep dose-response curve against medulloblastoma and glioma CNS tumour cell lines. Busulfan crosses the brain blood barrier with a CSF to plasma ratio of 1.39 when given a dose of 600 mg/m 2 . Recently, we showed that busulfan displayed anti tumour activity against medulloblastoma xenografts in athymic nude mice. Busulfan is administered orally every 6 h at a daily dose of 150 mg/m 2 for 4 consecutive days. Thiotepa is given as an 1-h infusion at a dose of 300 mg/m 2 /day for the next 3 days. ASCT is performed 48 hours after completion of HDC. Busulfaninduced seizures are prevented by the use of clonazepam. The specific toxicities of this regimen are cutaneous toxicity with erythro-melanodermia, severe gastrointestinal toxicity, the incidence of hepatic veno-occlusive disease is lower than after the combination of Busulfan with Melphalan. The toxic mortality rate of this HDC regimen is <10% and improved with
